Budesonide and Formoterol Fumarate Dihydrate Articles

Asthma preventive drugs market led by GlaxoSmithKline's Advair

26 November 2012

FDA's new safety controls for LABA-containing drugs will impact prescribing for the treatment of asthma

26 August 2010

US FDA updates labeling on long-acting beta-agonists, notably GSK’s Advair and Serevent and AstraZeneca’s Symbicort

3 June 2010

AstraZeneca settles over transfer pricing in UK, agreeing to pay £505 million; GSK slumps on Avandia news

23 February 2010

US FDA calls for new safety controls on long-acting asthma drugs that could hit sales potential

19 February 2010

Merck & Co’s new combo asthma drug expected to garner peak year sales of over $250 million

10 February 2010

Spiriva closes the gap in patient share with Advair for COPD treatment in USA

24 December 2009

AstraZeneca beats consensus forecasts with 3rd quarter 2009 profits up 22% raises forecasts

29 October 2009

Japanese approval for AstraZeneca/Astellas’ Symbicort; AZ fined $115 million in USA

16 October 2009

Nycomed and Forest Labs to commercialize Nycomed’s of Daxas’ Daxas for COPD in USA

11 August 2009

Astellas to co-promote AstraZeneca’s Symbicort in Japan

4 August 2009

AstraZeneca's 1st-qtr results beat forecasts, with 39% leap in reported EPS

1 May 2009

FDA asks for more info on Symbicort in young

7 April 2009

Stock Commentary - Europe - week to Mar 16, 2009

23 March 2009

Symbicort ups small airway function; study

23 March 2009

Symbicort approved in USA for COPD

9 March 2009

AstraZeneca's net income slips 1.6% in 4th qtr as generic competition starts to bite

9 February 2009

FDA panel votes against Foradil and Serevent, but backs Symbicort and Advair

22 December 2008

FDA divided on safety of Serevent and Foradil ahead of panel meeting

15 December 2008

AZ presents SHINE/SUN data at CHEST 2008

10 November 2008

AstraZeneca cheers investors, with 29% 3rd-qtr profits rise and increased target

10 November 2008

Symbicort sees similar safety to budesonide

1 September 2008

AstraZeneca's 2nd qtr beats consensus, helped by Crestor and Nexium

11 August 2008

AZ submits sNDA for Symbicot in pediatric asthma

9 June 2008

AstraZeneca reports strong results in Symbicort pediatric trial

26 May 2008

EPO revokes a Symbicort patent

12 May 2008

AstraZeneca set to meet 2008 targets, despite 1st-qtr profit decline

5 May 2008

AstraZeneca submits Symbicort sNDA to US FDA

5 May 2008

MAP0005 comparable FEV1 to Symbicort

14 April 2008

US FDA begins safety review of LABA asthma drugs

10 March 2008

Merck & Co sells JV products to AZ

10 March 2008

AstraZeneca's net profit falls 12% on restructing charges from MedImmune buy, lower Nexium sales

11 February 2008

Fostair launched in UK as cheaper than GSK/AZ asthma MDIs

28 January 2008

Charges and generics hit AstraZeneca's 3rd-qtr, as net profit falls 15%

12 November 2007

Symbicort patent blow for AstraZeneca

29 October 2007

Stock Commentary - Europe - week to October 22, 2007

29 October 2007

Posting solid 2nd-qtr results, AstraZeneca announces another cost-cutting program

6 August 2007

Stock Commentary - Europe - week to July 2, 2007

9 July 2007

CORRECTION: AstraZeneca's Symbicort

9 July 2007

AstraZeneca's Symbicort available in the USA

2 July 2007

SMC clears Symbicort SMART for asthma

18 June 2007

AstraZeneca launches Symbicort SMART in UK

4 June 2007

AstraZeneca bids $15.6B for MedImmune; posts 13% 1st-qtr 2007 EPS rise

30 April 2007

AstraZeneca's CEO reviews Japan ops

5 March 2007

AstraZeneca posts strong sales and earnings but announces 3,000 job cuts

12 February 2007

AstraZeneca welcomes updated GINA guidelines

20 November 2006

AstraZeneca fails to please, despite posting a 34% rise in 3rd-qtr 2006 earnings

6 November 2006

AstraZeneca completes Symbicort SMART MRP

16 October 2006

AstraZeneca's Symbicort reduces exacerbations

11 September 2006

New data challenges asthma management paradigm

4 September 2006

AstraZeneca's shares dip despite 41% rise in EPS, as CEO's guidance disappoints

7 August 2006

Symbicort gets US OK for asthma maintenance

31 July 2006

AstraZeneca's Symbicort SMART OKed in Australia

24 July 2006

Symbicort plus beta 2 agonist shows promise in COPD

10 July 2006

Strong data for AstraZeneca's Symbicort

3 July 2006

COPD drugs predominate in AstraZeneca's early-stage pipeline; CytoFab nears Ph III

19 June 2006

COPD market set to grow 9% a year to reach $12B by 2014

17 April 2006

AstraZeneca welcomes TORCH trial results

3 April 2006

AstraZeneca profit leaps 30% but firm admits thin pipeline

6 February 2006

Innovata secures L25M Duohaler asthma deal

19 December 2005

Astra Zeneca 2nd-qtr pretax profit leaps 67%

8 August 2005

AstraZeneca sees 2nd-qtr pretax profit leap 67%

1 August 2005

AstraZeneca: Symbicort "more effective than Seretide"

30 May 2005

EPO: Astra's Symbicort patent still valid

23 May 2005

AstraZeneca beats forecasts as troubled Crestor sees 1st-qtr sales double

9 May 2005

GlaxoSmithKline sees 1st- qtr EPS rise 19%, as generic woes diminish

9 May 2005

AstraZeneca and GSK spar on asthma drugs

4 April 2005

Despite a tough year, AstraZeneca's full-year 2004 results fall in target range

7 February 2005

Symbicort effective in asthma control

24 January 2005

GlaxoSmithKline outperforming UK rival AstraZeneca, say SG Cowen analysts

17 January 2005

AstraZeneca's 2nd-qtr sales jump 19%

2 August 2004

Cost-effectiveness of COPD combination therapies

7 June 2004

AstraZeneca forecasts good growth in Spain

3 May 2004

AstraZeneca's 1st-qtr sales pass $5 billion

3 May 2004

Benefits of Symbicort single inhaler revealed

29 March 2004

AstraZeneca forecasts sharp rise in earnings but shares slip on mediocre Crestor sales

9 February 2004

AstraZeneca files Symbicort asthma treatment concept in EU

22 December 2003

Positive new data for adjustable Symbicort

15 September 2003

Symbicort trial data for COPD and asthma

26 May 2003

Symbicort launched for COPD in UK

7 April 2003

Despite Losec competition AstraZeneca reports 7% hike in 2002 earnings

10 February 2003

Oxis Turbuhaler OKed for COPD across EU

13 January 2003

AstraZeneca's Symbicort 100/6 Turbohaler granted UK license for use in children

12 August 2002

Declining drug launches in Europe drives imperative for sustained lifecycle pricing

22 July 2002

Adolescent use OKed for Symbicort in UK

22 April 2002

AstraZeneca's Symbicort cleared in Canada

18 February 2002

AstraZeneca confident about overcoming loss of Prilosec revenues

11 February 2002

AstraZeneca highlights key product growth over the next five years

6 December 2001

"Robust" year for AstraZeneca

5 December 2001

World asthma therapy markets to 2010

20 November 2001

GSK launches Advair for asthma in USA; major marketing push planned

18 April 2001

Stock Commentary - Europe

11 January 2001

AstraZeneca asthma drug approved in EU

9 January 2001

AstraZeneca gains first Symbicort OK

29 August 2000

AstraZeneca files for Symbicort approval

15 December 1999

AstraZeneca unveils promising portfolio with 57 NCEs

14 December 1999

Positive 1st-qtr news from AstraZeneca

26 May 1999

Jan Lundberg tells the Marketletter how AstraZeneca is turning around its pipeline